Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

OBJECTIVE: Nicotinic acetylcholine receptors are possible therapeutic targets for schizophrenia, as shown by neurobiological and molecular evidence for deficiencies in expression of α(7)-nicotinic receptors. Patients’ heavy smoking suggests attempted self-medication through this mechanism. The agent...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Freedman, Robert, Olincy, Ann, Buchanan, Robert W., Harris, Josette G., Gold, James M., Johnson, Lynn, Allensworth, Diana, Guzman-Bonilla, Alejandrina, Clement, Bettye, Ball, M. Patricia, Kutnick, Jay, Pender, Vicki, Martin, Laura F., Stevens, Karen E., Wagner, Brandie D., Zerbe, Gary O., Soti, Ferenc, Kem, William R.
Format: Artigo
Idioma:Inglês
Publicat: 2008
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3746983/
https://ncbi.nlm.nih.gov/pubmed/18381905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1176/appi.ajp.2008.07071135
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars